Canadian trade union Unifor said roughly 4,500 of its members have been temporarily laid off because of the GM strike so far.Autosread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Roku shares have more than quadrupled this year, but the stock has had some rocky days of late as more players jump into streaming.Technologyread more
Legal experts say that California, which has pledged to sue, has a strong case that the administration's move is unlawful.Politicsread more
A group of 23 states on Friday sued to undo the Trump administration's determination that federal law bars California from setting stiff tailpipe emission standards and...Transportationread more
U.S. officials, including Secretary of State Mike Pompeo, have accused Iran of orchestrating devastating strikes on Saudi oil installations over the weekend.Politicsread more
Rosengren was one of two central bank officials to vote against Wednesday's quarter-point rate reduction, and explained in a speech to the Stern School of Business at New York...Economyread more
Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Apple's iPhone 11 ships with a slow charger in the box, but it supports fast charging. So buy this cable and charger to get a 50 percent charge in 30 minutes.Technologyread more
The process will involve three 14-day operations involving $30 billion as well as continued overnight operations of at least $75 billion each.The Fedread more
Some businesses, mostly small to midsize companies, are providing workers with paid time off to join the global climate strike, while others are shutting down operations...Weather & Natural Disastersread more
An experimental drug from Eli Lilly failed to slow the loss of cognitive ability in patients with mild Alzheimer's disease, the company said Wednesday.
Shares of Lilly shed 10.5 percent on Wednesday following the report.
Based on the failure of the more than 2,100 patient study in Phase III clinical trials, Lilly said it won't seek U.S. approval of solanezumab, the infused drug for mild dementia.
Outgoing Eli Lilly CEO John Lechleiter told CNBC on Wednesday that solanezumab's failure is a disappointment for Alzheimer's sufferers, but the company has other potential treatments for the disease in the pipeline.
"We have an oral drug we're testing now in Phase III. We have five other therapeutic agents in early stages of development," said Lechleiter, who is retiring at the end of the year.
It could take "weeks or months" to figure out what went wrong with solanezumab, he said on "Squawk Box."
Incoming CEO David Ricks told "Squawk Box" that Lilly had been planning for this worst-case scenario, and still expects to grow without the drug.
"We knew it was a high-risk, high-reward program. We're disappointed with the results," Ricks said. "We have a lot going on beyond Alzheimer's, launches in diabetes and oncology and immunology."
Ricks said Lilly stands by July projections, calling for revenues to grow an average of 5 percent between by the end of the decade, and calling for margins to improve without solanezumab. "That's still intact," he said.
Some analysts had predicted solanezumab, if approved, would have eventually led to more than $5 billion in annual sales and a boost to Lilly's earnings for years to come.
Lilly said the study outcome is expected to result in a fourth quarter pretax charge of about $150 million, adding the company plans to provide updated 2016 financial guidance and announce 2017 guidance on Dec. 15.
Shares of Biogen, which is developing a similar drug, declined more than 3 percent during the session.
— Reuters contributed to this report